HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$9.82
0.42 (4.47%)
▲
5d:
+5.93%
30d:
+12.87%
90d:
-1.5%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
26d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.01
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$8.70
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $9.82, which is considered extended relative to its 30-day fair value range of $8.87 to $9.34. The stock's valuation (Forward PE: 16.2) is in line with its historical norms (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This pessimistic expectation contrasts with the company's recent 92.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $9.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: HLN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.69 (+19.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $9.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: HLN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.69 (+19.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.87 -
$9.34
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
59.5%
All Signals
- BEARISH: Price extended above range (+5.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.5%)
- BULLISH: Trading below Wall St target ($11.69)
Trading Range Analysis
30-Day Trading Range
$8.87 -
$9.34
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.77
Resistance Level
$9.82
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.25
Wall Street Target
$11.69
(+19.0%)
Revenue Growth (YoY)
0.6%
Earnings Growth (YoY)
92.0%
Profit Margin
15.1%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
16.3 vs 16.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$9.72
(-1%)
2-Year Target
$9.62
(-2%)
3-Year Target
$9.53
(-3%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$9.79
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.6%)
$17.34
(+77%)
Base:
(SPY PE: 16.2, Growth: 9.6%)
$12.93
(+32%)
Bear:
(PE: 13.8, Growth: 9.6%)
$10.99
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 19.18 | Current EPS (TTM): $0.49
Bull Case
$12.75
(+30%)
Analyst growth 23.3%, PE expands to 21.1
Base Case
$11.59
(+18%)
Market implied 23.3%, PE stable at 19.2
Bear Case
$6.39
(-35%)
Severe decline -20.0%, PE contracts to 16.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.2 to 16.7
Stabilization Target:
$10.09
(+2.8%)
PE Expansion Potential:
+2.8%
Share & Embed Analysis
Last updated: July 03, 2026 6:55 PM ET
Data refreshes hourly during market hours. Next update: 7:55 PM
Data refreshes hourly during market hours. Next update: 7:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
